BACKGROUND: Human immunodeficiency virus (HIV)-associated nephropathy (HIVAN), characterized by a fulminant form of focal segmental glomerulosclerosis, has become the third leading cause of end-stage renal disease (ESRD) in young African Americans. There is a theoretical possibility that hemodialysis (HD) therapy in these patients may enhance HIV replication through the activation of white blood cells and release of such cytokines as tumor necrosis factor-alpha, interleukin-1, and interleukin-6, which have been found to increase HIV replication in vitro. We therefore determined whether dialysis modality is a factor in the survival of patients with HIVAN and ESRD. METHODS: Information regarding dialysis modality was available for 6,053 of 6,166 patients with ESRD and HIVAN who started dialysis therapy in the United States from December 1995 to December 1999 by using the US Renal Data System database. RESULTS: Eighty-nine percent were black. Eighty-eight percent underwent HD, and 12%, peritoneal dialysis (PD). On Cox-proportional hazard analysis, after adjusting for demographic variables and year of dialysis therapy initiation, there was no difference in survival between the different modalities (PD versus HD: hazard ratio, 1.01; 95% confidence interval, 0.91 to 1.13). In addition, on censoring patients at the time of first dialysis modality switch, no difference in survival was found between PD and HD. CONCLUSION: We conclude that patients with HIVAN and ESRD should be given an option to choose dialysis modality because it is not a factor in predicting survival.
BACKGROUND:Human immunodeficiency virus (HIV)-associated nephropathy (HIVAN), characterized by a fulminant form of focal segmental glomerulosclerosis, has become the third leading cause of end-stage renal disease (ESRD) in young African Americans. There is a theoretical possibility that hemodialysis (HD) therapy in these patients may enhance HIV replication through the activation of white blood cells and release of such cytokines as tumor necrosis factor-alpha, interleukin-1, and interleukin-6, which have been found to increase HIV replication in vitro. We therefore determined whether dialysis modality is a factor in the survival of patients with HIVAN and ESRD. METHODS: Information regarding dialysis modality was available for 6,053 of 6,166 patients with ESRD and HIVAN who started dialysis therapy in the United States from December 1995 to December 1999 by using the US Renal Data System database. RESULTS: Eighty-nine percent were black. Eighty-eight percent underwent HD, and 12%, peritoneal dialysis (PD). On Cox-proportional hazard analysis, after adjusting for demographic variables and year of dialysis therapy initiation, there was no difference in survival between the different modalities (PD versus HD: hazard ratio, 1.01; 95% confidence interval, 0.91 to 1.13). In addition, on censoring patients at the time of first dialysis modality switch, no difference in survival was found between PD and HD. CONCLUSION: We conclude that patients with HIVAN and ESRD should be given an option to choose dialysis modality because it is not a factor in predicting survival.
Authors: Gregory M Lucas; Michael J Ross; Peter G Stock; Michael G Shlipak; Christina M Wyatt; Samir K Gupta; Mohamed G Atta; Kara K Wools-Kaloustian; Paul A Pham; Leslie A Bruggeman; Jeffrey L Lennox; Patricio E Ray; Robert C Kalayjian Journal: Clin Infect Dis Date: 2014-09-17 Impact factor: 9.079
Authors: Charles R Swanepoel; Mohamed G Atta; Vivette D D'Agati; Michelle M Estrella; Agnes B Fogo; Saraladevi Naicker; Frank A Post; Nicola Wearne; Cheryl A Winkler; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christina M Wyatt Journal: Kidney Int Date: 2018-02-03 Impact factor: 10.612